Maybe Vertex Pharmaceuticals
The clinical trial data Vertex released this week came from several phase 2 studies of telaprevir, conducted ahead of the American Association for the Study of Liver Diseases medical conference in early November. The most important tidbit from Vertex and its telaprevir marketing partner, Johnson & Johnson
That's a big deal, because it's been shown that patients are better at taking medicine when they have to take it less often. And if patients don't take their compounds as prescribed, serious complications can arise, especially with infectious diseases.
Until this result came out, a drawback of telaprevir was that some of its future potential hepatitis C antiviral competitors -- from drugmakers such as InterMune and Schering-Plough
This result is important for both telaprevir and Vertex's future. Because telaprevir is Vertex's lead drug, the stock price will shift as the drug's fortunes do.
Vertex and InterMune are active picks of our Rule Breakers newsletter service. You can check out all of our other recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.